Overview

Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Assessment of the safety and the efficacy of a tacrolimus modified release (FK506MR) based immunosuppressive regimen in stable kidney transplant subjects converted from a cyclosporin based immunosuppressive regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Cyclosporine
Cyclosporins
Tacrolimus